Methods using RANK/RANKL antagonist antibodies for treating pain
View Patent ↗Disclosed herein are methods of treating pain using comprising RANK/RANKL antagonists.
1. A method of treating or relieving osteoarthritis pain, low back pain, or pain from complex regional pain syndrome in a mammal in need thereof, comprising administering an antibody to the mammal, wherein the antibody:
a) is denosumab; or
b) has binding specificity to RANKL and competes with denosumab for binding to RANKL.
2. The method of claim 1 , wherein the antibody is a monoclonal antibody.
3. The method of claim 2 wherein the monoclonal antibody is a human antibody, a humanized antibody, or a chimeric antibody.
4. The method of claim 1 , wherein the antibody has binding specificity to RANKL.
5. The method of claim 1 , wherein about 0.05 mg/kg to about 3 mg/kg of the antibody is administered to the mammal being within a four week period.
6. The method of claim 5 , where about 0.1 mg/kg to about 20 mg/kg of the antibody is administered.
7. The method of claim 1 , wherein the antibody is administered no more than once a week.
8. The method of claim 1 , wherein the antibody is administered daily, weekly, monthly, every three months, every six months, or every year.
9. The method of claim 1 , wherein the method is a method of relieving osteoarthritis pain.
10. The method of claim 9 , wherein the osteoarthritis affects a knee.
11. The method of claim 1 , wherein the method is a method of relieving pain from complex regional pain syndrome.
12. The method of claim 1 , wherein the method is a method of relieving low back pain.
13. The method of claim 1 , wherein the antibody comprises a) a heavy chain comprising CDR1, CDR2, and CDR3 of SEQ ID NO: 3; and b) a light chain comprising CDR1, CDR2, and CDR3 of SEQ ID NO: 4.
14. The method of claim 1 , wherein the mammal experiences pain relief within about three months after the antibody is first administered.
15. The method of claim 1 , wherein the antibody comprises a RANKL-binding fragment.
16. The method of claim 15 , wherein the RANKL-binding fragment is a Fab, a Fab′, a F(ab′) 2 , a Fv fragment, a diabody, a linear antibody, or a single-chain antibody molecule.
17. The method of claim 1 , wherein the antibody partially or fully blocks, inhibits, or neutralizes a biological activity of RANKL.
18. The method of claim 1 , wherein the mammal experiences pain relief for at least 24 hours.
19. The method of claim 1 , wherein the antibody is denosumab.
20. The method of claim 1 , wherein the antibody has binding specificity to RANKL and competes with denosumab for binding to RANKL.
21. The method of claim 1 , wherein the mammal is a human being.
22. The method of claim 1 , wherein the antibody that
has binding specificity to RANKL and competes with denosumab for binding to RANKL
has at least about 90% sequence identity to denosumab.
23. The method of claim 1 , wherein the antibody that
has binding specificity to RANKL and competes with denosumab for binding to RANKL
has at least about 95% sequence identity to denosumab.
24. The method of claim 1 , wherein the antibody that
has binding specificity to RANKL and competes with denosumab for binding to RANKL;
has at least about 99% sequence identity to denosumab.